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Pathological accumulation of 27-carbon intermediates or end-products of cholesterol metabolism,
named oxysterols, may contribute to the onset and especially to the development of major chronic
diseases in which inﬂammation, but also oxidative damage and to a certain extent cell death, are
hallmarks and primary mechanisms of progression. Indeed, certain oxysterols exercise strong
pro-oxidant and pro-inﬂammatory effects at concentrations detectable in the lesions typical of athero-
sclerosis, neurodegenerative diseases, inﬂammatory bowel diseases, age-related macular degeneration,
and other pathological conditions characterized by altered cholesterol uptake and/or metabolism.
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In order to degrade cholesterol to more polar compounds, which
are more easily disposable by the cell, an oxygen function, such as a
hydroxyl, epoxide or ketone group, is introduced into the sterol
nucleus or side chain. The resulting 27-carbon intermediates or end-
products of cholesterol metabolism are called oxysterols [1].
Of interest in pathophysiology, these compounds in general show
a biochemical reactivity that is one or even two orders of magnitude
higher than that of the parent compound. Further, due to the
additional oxygen function, oxysterols are readily able to cross
lipophilic membranes, unlike cholesterol [2,3]. Thus, if their produc-
tion in cells and tissues and/or their introduction with dietary
animal fat are excessive, oxysterols could indeed contribute to the
pathogenesis of various disease processes.
As schematically illustrated in Table 1, oxysterols may be
originally present in food containing animal fat, but they are
chieﬂy generated during food storing and cooking. The oxysterolsD license. 
Table 1
Origin of plasma and tissue oxysterols.
From the diet
Already present in food (e.g. red meat, egg, milk, cheese, ham)
Formed by auto-oxidation of foodstuffs (induced by heat, light exposure, refrigeration, freeze-drying)
Endogenous sources
(1) Non-enzymatic pathways
Cholesterol attack by reactive oxygen species, by peroxyl and alkoxyl radicals
Oxidation by leukocyte/H2O2/HOCl system (during inﬂammatory processes)
(2) Enzymatic pathways
Cholesterol oxidation mediated by cholesterol 24-hydroxylase (cytochrome P450-46A1), mainly in the brain, or by cholesterol 27-hydroxylase (cytochrome P450-27A1)
and 7a-hydroxylase cytochrome P450-7A1) in various tissues
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in human pathology.With regard to endogenous sources of oxysterols,
oxidation of the sterol ring of cholesterol is almost always non-
enzymatic, leading to compounds like 7-ketocholesterol (7-K), 7b-
hydroxycholesterol (7b-OH), 5a,6a-epoxycholesterol (a-EPOX) and
5b,6b-epoxycholesterol (b-EPOX). Conversely, 7a-hydroxycholesterol
(7a-OH) is produced via an enzymatic mechanism, as are all oxyster-
ols deriving from the oxidation of the side chain, e.g. 24-
hydroxycholesterol (24-OH) and 27-hydroxycholesterol (27-OH) [4,5].Pro-inﬂammatory effect of oxysterols
The oxysterols of interest in pathophysiology, of which the main
ones are listed above, are unanimously recognized as strongly
enhancing inﬂammatory reactions, by inducing both expression and
synthesis of inﬂammatory cytokines, including tumor necrosis factor-
a (TNF-a), interleukin-1b (IL-1b) and interleukin-6 (IL-6), chemo-
kines such as interleukin-8 (IL-8), monocyte chemotactic protein-1
(MCP-1) and monocyte inﬂammatory protein-1b (MIP-1b), and
adhesion molecules, including intercellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and
E-selectin [6]. Notably, the expression of these and other inﬂamma-
tory mediators is closely dependent on the activity of nuclear factor-
kB (NF-kB), a transcription peptide demonstrated to be strongly
up-regulated by oxysterols, through activation of the protein kinase
C-extracellular signaling-regulated kinase 1/2 (PKC-ERK1/2) path-
way [7]. This does not mean that other transcription factors, for
example activator protein-1 (AP-1), are not also important in mod-
ulating the expression of inﬂammation-related cytokines. Very
recently, a mixture of oxysterols similar to that detectable in human
atherosclerotic lesions has been conﬁrmed to up-regulate AP-1, and
not only NF-kB, in human promonocytic cells [8].
Inﬂammation is undoubtedly a major driving force for the
progression and complication of major chronic diseases. The
recruitment and activation of phagocytes, characteristic of inﬂam-
matory reactions, lead to an increased steady-state level of radical
and non-radical reactive oxygen species (ROS), that
in turn amplify inﬂammation, giving rise to a vicious circle that
sustains and expands the inﬂammatory process. The ﬁrst important
consequence of this event is that any inﬂammatory process
determines a shift of the biochemical redox equilibrium in cells
and tissues towards an excess of oxidative reactions, and oxidative
stress is the main endogenous mechanism of non-enzymatic gen-
eration of oxysterols. As a second notable consequence, the reci-
procal ability of inﬂammation and oxysterols to up-regulate one
another, tends to amplify the overall inﬂammatory process:
inf lammation-oxidative stress-cholesterol oxidation-inf lammationThis scheme is probably too simple, since the actual interac-
tion between inﬂammation and cholesterol is most likely further
complicated, in disease processes for which hypercholesterole-
mia, i.e. a perturbation of cholesterol metabolism, is a risk
factor. These include atherosclerosis, but also Alzheimer’s and
Parkinson’s diseases, inﬂammatory bowel diseases and colon
cancer, alcoholic and non-alcoholic steatosis and steatohepatitis. In
addition, at least in the brain, the enzymatic production of oxyster-
ols is remarkable already under physiological conditions [9].Cholesterol oxidation in the pathogenesis
of atherosclerosis
Hypercholesterolemia has long been related to the pathogen-
esis of atherosclerosis, but the actual mechanism by which
cholesterol favors both the initiation and the progression of this
disease is still debated. The epidemiologic evidence supporting
cholesterol as a primary risk factor of cardiovascular diseases has
not been validated thus far by available biochemical data, which
clearly indicate cholesterol as a poorly reactive molecule.
Conversely, especially in the last 10–15 years, a number of
experimental studies have consistently shown that cholesterol
oxidation products, in particular oxysterols, possess a much
higher biochemical reactivity than that of the parent com-
pound [4]. This evidence prompted several research groups to
focus on the potential modulation of atherosclerotic disease, by
the oxysterols that have been detected in the blood of hyperch-
olesterolemic individuals and in human atheromas [10,11].
Oxysterols, like other lipid oxidation products, have been shown
to contribute to the endothelial cell dysfunction that charac-
terizes the onset of the atheromasic plaque [12]. In particular, the
oxysterols 7a-OH, 7b-OH and 7-K have been demonstrated to
induce a clear inﬂammatory phenotype in human endothelial
cells [13], and 7-K induces foam cell formation [14]. With regard
to the molecular signaling underlying these effects of oxysterols,
the central role played by PKCd and by ERK1/2 pathway was
conclusively demonstrated through small interfering RNA (siRNA)
technology [15].
More recently, together with metalloproteases implicated in
the pathogenesis of major human diseases, the potential impact
of oxysterols on atherosclerotic plaque erosion and rupture has
received increasing attention. In this connection, the evidence of
over-expression of matrix metalloproteinase-9 (MMP-9) in
freshly isolated human monocytes, activated in vitro by incuba-
tion with phorbol myristate acetate, is of particular interest. This
treatment is known to enhance NADPH oxidase isoform 2 (Nox2)
in phagocytes. Induction of MMP-9, an independent risk factor for
atherothrombotic events [16], was then shown to depend on
stimulation of Nox2, since inactivation of the latter enzyme with a
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metalloproteinase [17]. Indeed, some years previously, mouse
peritoneal macrophages, incubated in the presence of a mixture of
oxysterols of biological relevance, were shown to markedly
increase ROS intracellular steady-state, by activating Nox2 [18].
These results were later reproduced in human promonocytic cells
challenged with either an oxysterol mixture or 27-OH or 7a-OH
given alone [8], thus conﬁrming that certain oxysterols may also
exert a direct and marked pro-oxidant effect. Notably, oxysterols
have been shown to enhance MMP-9 levels and activity in human
cells of the macrophage lineage, through the induction of Nox2
activity and, consequently, of ROS production. However, they did
not modify levels of the tissue inhibitors of metalloproteinases,
TIMP-1 and TIMP-2 [8].
In an earlier study, a similar increase in the MMP-9/TIMPs
ratio was observed in human advanced atherosclerotic lesions
causing stable angina or an acute coronary syndrome, but the
molecules responsible for this imbalance have not yet been
investigated [19]. Most likely, other lipid oxidation products
generated within oxidized low density lipoprotein (LDL) may also
exert similar effects, which may not necessarily be limited to
MMP-9. Be that as it may, extensive oxysterol-mediated degrada-
tion of extracellular matrix components of the ﬁbrotic cap of
advanced atheromas would render them unstable and prone to
rupture.
Fig. 1 shows the main signaling pathways that are up-
regulated by the oxysterols detectable in atherosclerotic plaques
and leading to increased expression and levels of MMP-9, inﬂam-
matory cytokines (e.g. MCP-1, IL-8, IL-1b) and scavenger receptor
CD36. Compounds such as 7a-OH and 27-OH activate the PKCd
isoform as well as the classic isoforms, involving a G-protein andpERK/pJNK
AP-1/NF-κB , ..
MMP-9
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Fig. 1. Signaling molecules involved in oxysterol-mediated up-regulation of MMP-
9, inﬂammatory cytokines, and CD36. The involvement of signaling molecules and
transcription factors in the up-regulation of MMP-9, inﬂammatory cytokines, and
CD36 has been validated through the transfection or treatment of human
promonocytic cells, with speciﬁc siRNAs or inhibitors respectively. Rotenone,
inhibitor of mitochondrial respiratory chain complex I; DPI, diphenyleneiodonium
chloride, inhibitor of NADPH oxidases; PD98059, inhibitor of MEK; SP600125,
inhibitor of JNK; parthenolide, inhibitor of NF-kB.the phospholipase C-dependent cascade [8,15]. Activation of the
PKC family isoenzymes drives oxysterol-generated signals
through the mitogen-activated protein kinase (MAPK) pathway,
with marked up-regulation of ERK and c-Jun N-terminal (JNK)
kinases, but apparently without modulating p38 kinase [8].
Another PKC-driven effect is a sustained up-regulation of Nox2,
with consequent excessive production of ROS. ROS overproduc-
tion, due to Nox2 but also to impaired mitochondrial respiration,
certainly contributes to mediating and amplifying oxysterol-
induced signaling through the cell, with eventual activation of
redox-sensitive transcription factors. Among these transcription
peptides, experimental data obtained thus far clearly indicate the
involvement of NF-kB and AP-1. The involvement of these
enzymes and transcription peptides has been demonstrated in
human promonocytic cells, using speciﬁc inhibitors and/or
siRNAs [8]. Increasing data, obtained in our laboratory, suggest
that the same signaling pathway might be up-regulated by
cholesterol oxides in other cell types, such as neuronal cells and
epithelial colonic cells.Altered cholesterol metabolism, oxysterols and
neurodegenerative diseases
As has been said, hypercholesterolemia has long been con-
sidered to act as the primary risk factor for developing Alzhei-
mer’s disease and, possibly, Parkinson’s disease [20,21]. Further,
impaired brain cholesterol distribution and metabolism has more
recently been pointed to as likely involved in the pathogenesis of
these and other neurodegenerative diseases [22,23]. Oxysterols
could play a very important role in brain pathophysiology since,
unlike cholesterol, they can permeate the blood–brain barrier [24].
Although this fact means that the brain can eliminate excess
amounts of these oxidation products, it could conversely allow
toxic amounts of oxysterols, present in the blood stream, to
accumulate in the brain. The latter event has been deﬁnitely
demonstrated for 27-OH [25].
To date, the oxysterols most widely considered to be poten-
tially implicated in the pathogenesis of neurodegenerative disease
processes are 24-OH and 27-OH, both of enzymatic origin [4,5]
and good ligands of the liver X receptors (LXRs) [26]. This class of
receptors is now recognized as very important, although their
multifaceted physiological role has yet to be fully elucidated [27].
The oxysterol 24-OH is produced by cholesterol 24-hydroxylase
(cytochrome P450-46A1), a fairly speciﬁc brain enzyme, essen-
tially (at least in the normal brain) localized in neuronal cells.
To date it has been considered to exert a protective action in the
central nervous system, mainly it may favor the efﬂux of excess
cholesterol from the brain to the blood [9].
However, the same oxysterol has recently been shown to
markedly potentiate both the pro-apoptotic and the pro-
necrogenic effects exerted by 1–42 amyloid-b (Ab1–42) peptide
on two different human neuronal cell lines [28] but also on
human dental pulp progenitor cells differentiated into neuronal-
like cells [29]. In those in vitro experimental models, 24-OH
(1 mM) appeared to interact with Ab1–42 by strongly increasing
intracellular ROS steady-state [28]. This evidence ﬁts the widely-
held opinion that Ab needs to form oligomers to induce neuro-
toxicity, and that the latter process is probably enhanced by
oxidative redox imbalance [30]. In this connection, the histo-
chemical observation of a prevalent localization of cytochrome
P450-46A1 in the vicinity of amyloid deposits, in autoptic brain
samples from Alzheimer’s patients, is of interest [31]; oxidative
stress/lipid peroxidation appear implicated in this disease from
its early onset [32,33].
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enzyme that generates 27-OH, is present in various tissues [9].
Accumulation in the brain of 27-OH, either deriving from the
blood in hypercholesterolemic subjects, or generated in situ, has
been reported to be potentially toxic, and to be associated with
Alzheimer’s disease [34]. In the various in vitro tests performed in
our laboratory, 27-OH often displayed lower neurotoxicity than
did 24-OH [28]. Most likely, the actual effect of an abnormal
accumulation of 24-OH or 27-OH depends on a series of factors,
i.e. localization in the brain, co-presence of oxidative redox
imbalance, iron accumulation, relative antioxidant depletion, etc.
Moreover, a study of some years ago reported that the Ab
peptide and, to a lesser extent, also the amyloid precursor protein,
induced generation of 7b-OH [35].
In a very recent retrospective study carried out in cardiovas-
cular patients with evidence of cerebrovascular disease, higher
plasma levels of 24-OH and a greater ratio of 24-OH/27-OH are
associated with the development of incident cognitive impair-
ment over eight years of follow-up [36]. These ﬁndings heavily
implicate a perturbation of cholesterol metabolism in the early
stages of neurodegenerative disease process, including Alzhei-
mer’s disease development.
Recent lipidomics analysis on human Parkinson’s disease
brains found an increased amount of oxysterols selectively
localized in the visual cortex. Interestingly, 24-OH and 27-OH
were not the only two oxysterols increased, the levels of 7a-OH,
7b-OH, b-EPOX and 7K also being increased about two fold in
Parkinson’s disease brains versus control brains [37]. This study,
in our opinion, has the merit of expanding the viewpoint when
examining oxysterols potentially implicated in the pathogenesis
of neurodegenerative diseases. This recent approach, considering
also oxysterols of non-enzymatic origin, appears to be valid,
because of the recognized involvement of oxidative stress in both
the initiation and the progression of brain degenerative disease
processes [32,33].Oxysterols and inﬂammatory bowel diseases
The strong pro-inﬂammatory and pro-apoptotic properties
exerted by excessive levels of several oxysterols have recently
been conclusively demonstrated; this has provided new insight
into the mechanisms of progression of human disease processes
that are sustained by chronic inﬂammatory reactions. Ulcerative
colitis and Crohn’s disease, two frequent chronic diseases of the
gut classiﬁed within the group of inﬂammatory bowel diseases
(IBD), could easily be favored and worsened by a cholesterol-rich
dietary regimen, typical of the Western diet. Bearing this in mind,
Biasi and colleagues showed that a mixture of oxysterols stem-
ming from the heating of dietary cholesterol, comprising 7-K,
7a-OH, 7b-OH, a-EPOX and b-EPOX, led differentiated human
epithelial colonic cells (CaCo-2 cells) to apoptotic death. Speciﬁ-
cally, caspase-3 activation after cell challenge, in the presence of
the oxysterol mixture, was found to be 30–40% higher than in
untreated cells [38]. The observed pro-apoptotic effect was
prevented when up-regulation of Nox1 was inhibited; Nox1 is
the intestinal isoform of NADPH oxidase, and its activation
increases intracellular ROS steady-state [38]. The same oxysterol
mixture (30 mM), but also one of its component, i.e. 7b-OH
(4.4 mM), also exhibited a strong pro-inﬂammatory effect on
differentiated CaCo-2 cells, causing the rapid over-expression of
several inﬂammatory cytokines, namely IL-1a, IL-6, IL-8, IL-23,
MCP-1, transforming growth factor b1 (TGFb1), but apparently
not TNF-a nor IL-10 [39].
Whether involved or not in the onset of IBD, dietary oxysterols
most likely contribute to its ampliﬁcation and furtherdevelopment. In addition, up-regulation of TGFb1 in human
colonic cells by oxysterols might induce the selective growth
and development of atypical cell clones, resistant to the differ-
entiating and pro-apoptotic effects of this cytokine, thus favoring
colon cancer progression [40].Oxysterols in degenerative changes of the retina
The potential implication of oxysterols in age-related macular
degeneration (AMD), in particular those generated by non-
enzymatic reactions like 7-K, has recently been systematically
analyzed and reviewed [41]. The strong pro-oxidant, pro-inﬂam-
matory, and pro-apoptotic properties of relatively high amounts
of 7-K have been conﬁrmed in vitro, using human retinal ARPE.19
cells. Other active oxysterols are 7b-OH and 25-OH. Of interest, as
for epithelial colonic cells [39], the inﬂammatory cytokine most
strongly enhanced by oxysterols in retinal cells was IL-8, while no
signiﬁcant effect was detected with regard to TNF-a and IL-10
synthesis and secretion [42].
An increasing bulk of data thus suggest that an altered
cholesterol metabolism, with abnormal accumulation of oxyster-
ols, could also be an important pathogenetic factor in the case of
AMD. Further, since the main source of lipids in the retina appears
to be plasma LDL [41], which is very rich in cholesterol, hyperch-
olesterolemia might promote the expression of AMD. In this
connection, a cholesterol-rich diet has been demonstrated to
cause AMD-like retinal degeneration in the rabbit [43].
Of note, since accumulation of Ab also occurs in AMD, it now
appears likely that the peptide’s neurotoxicity is potentiated by
oxysterols, although this is yet to be conﬁrmed.Oxysterols and disease processes characterized by oxidative
redox imbalance
An overview of recent literature on the main biochemical
effects and potential pathogenic roles of various oxysterols
suggests that these cholesterol metabolites might contribute,
perhaps even signiﬁcantly, to the expression and development
of all disease processes promoted by inﬂammation and oxidative
stress. It is thus likely that oxysterols will in the near future be
given much more consideration when investigating the mechan-
isms leading to the onset and the progression of diseases such as
obesity, diabetes mellitus, alcoholic and non-alcoholic fatty liver
diseases, hemochromatosis, and chronic obstructive pulmonary
diseases.
Brieﬂy, it is worth remembering that oxysterols deriving from
the oxidation of the side chain of cholesterol (e.g. 24-OH, 27-OH,
25-OH) are very good ligands of LXRs and farnesoid X receptors
(FXRs), whose hyperactivation is now recognized as implicated in
both diabetes mellitus and non-alcoholic fatty liver disease [44],
among others. Further, cholesterol synthesis has been shown to
increase in non-alcoholic fatty liver disease [45], a disease in the
progression of which oxidative stress, a signiﬁcant non-enzymatic
source of oxysterols, is certainly a primary factor [5]. Finally,
future research on ‘‘enzymatic oxysterols’’ is particularly promis-
ing with regard to the interaction of these molecules with nuclear
receptors, while the study of ‘‘oxidative stress oxysterols’’ could
provide new insights in the pathogenesis of major chronic
diseases in humans.
Conclusive remarks
As a ﬁnal point, it appears important to stress that, although
the majority of experimental studies have challenged cells or
G. Poli et al. / Redox Biology 1 (2013) 125–130 129tissues with individual oxysterols, in the living organism oxyster-
ols are present as mixtures, whether of endogenous or of
exogenous origin. Like many other molecules with biochemical
and/or pharmacological effects, oxysterols interact with one
another in such a way as to modulate the effect of such mixtures.
Quenching reactions among different components of oxysterol
mixtures have been reported with regard to the role of oxysterols
in atherosclerosis [46] and IBD progression [39].
Complex interactions of oxysterols likely occur in vivo, thus
in vitro results concerning biochemical properties of pathologic
amounts of individual oxysterols must be carefully weighed up
and, where possible, accompanied and/or followed by analogous
experiments with biologically compatible oxysterol mixtures.Acknowledgments
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